Oligosecretary Myeloma: Prevalence and Its Clinical Significance

Samsung Medical Center

Status: Completed

Conditions: Multiple Myeloma

Treatments: Other: oligosecretary

Study type: Observational

Funder types: Other

Identifiers

NCT02095379

2014-02-055

Details and patient eligibility

About

In this study, the investigators aim to investigate the prevalence and clinical course of oligosecretary myeloma.

Full description

Oligosecretary myeloma is a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day). Patients with oligosecretary myeloma do not have established methods for disease monitoring and clinical informations regarding oligosecretary myeloma are still largely unknown.

In this study, we aimed to investigate the prevalence and clinical course of oligosecretary myeloma.

Enrollment: 390 patients

Sex: All

Ages: 17 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• a subgroup of multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)
• available clinical data

Exclusion criteria

• patients without available clinical data

Trial design

390 participants in 1 patient group

oligosecretary

Description:

Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)

Treatment:

Other: oligosecretary